Life on Ibrance
Ibrance is a kind of drug called CDK4/6 inhibitor that has been publicly funded in New Zealand since April 2020. In this webinar, our expert panel discusses how Ibrance is used in treatment for advanced breast cancer, managing common side effects and the practicalities of being on Ibrance.
This webinar may also be helpful for those taking Kisqali (ribociclib) and Verzenio (abemaciclib).
Meet your panel
Dr David Porter is a medical oncologist at Auckland City Hospital. He discusses who is given Ibrance and when, and the clinical trial evidence around its use.
Karen Spells is a clinical nurse specialist working in oncology and with breast cancer patients. She gives advice on practicalities of appointments and tests and how to manage common side effects.
Cheryl Carr started Ibrance recently, while Jacquie Dabrowski has been on Ibrance since 2018. They share their experience of managing appointments, side effects and how it's impacted their lives.